Page 6 - Multiple Sclerosis Functional Composite News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Multiple sclerosis functional composite. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Multiple Sclerosis Functional Composite Today - Breaking & Trending Today

Clene Reports Second Quarter 2021 Operating and Financial Highlights

Clene Reports Second Quarter 2021 Operating and Financial Highlights
biospace.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from biospace.com Daily Mail and Mail on Sunday newspapers.

Salt Lake City , United States , Ann Arbor , Gwendolyn Schanker , Jerome Mertens , Bruce Mackle , Matthew Kiernan , Benjamin Greenberg , Valleriev Mclaughlin , Rob Etherington , Davidj Matlin , Shalom Jacobovitz , Clene Nanomedicine , Us National Academy Of Medicine , Division Of Cardiovascular Medicine , University Of Michigan , Pulmonary Hypertension Program , Trademark Office , Clene Inc , Lifesci Communications , University Of Texas Southwestern Medical Center , Security Venture Opportunities Fund , Lifesci Advisors , Company Board Of Directors , Capital Group , Clene Nanomedicine Inc ,

Clene Reports First Quarter 2021 Operating and Financial

Clene Reports First Quarter 2021 Operating and Financial Highlights
May 11, 2021 07:00 ET
| Source:
Clene Inc.
Clene Inc.
Salt Lake City, UNITED STATES
Interim Phase 2 data indicate that CNM-Au8 has a homeostatic effect on brain bioenergetics and support its potential to drive meaningful neurological functional improvements in MS patients
Awarded Michael J. Fox Foundation (MJFF) grant to accelerate development of CNM-Au8 as a treatment for Parkinson’s disease
Phase 2 RESCUE-ALS trial and Phase 2 target engagement trials in MS and PD remain on track for topline data in 2H 2021
Cash of $48.0 million as of March 31, 2021
SALT LAKE CITY, May 11, 2021 (GLOBE NEWSWIRE) Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of neurodegener ....

United States , Rob Etherington , Trademark Office , Clene Inc , Clene Nanomedicine Inc , Michaelj Fox Foundation , Interim Phase , Clene Nanomedicine , Massachusetts General Hospital , Rating Scale Revised , Low Contrast Letter Acuity , Multiple Sclerosis Functional Composite , Symbol Digit Modalities Test , Hole Peg Test , Foot Walk , Nasdaq Clnn , Clene Inc , ஒன்றுபட்டது மாநிலங்களில் , கொள்ளை ஈத்தரிங்டன் , முத்திரை அலுவலகம் , கிளீன் இன்க் , இடைக்கால கட்டம் , மாசசூசெட்ஸ் ஜநரல் மருத்துவமனை , குறைந்த மாறாக கடிதம் கூர்மை , பல ஸ்க்லரோசிஸ் செயல்பாட்டு கலப்பு , சின்னம் இலக்க முறைகள் சோதனை ,

Clene Reports Full Year 2020 Operating and Financial Highlights

Clene Reports Full Year 2020 Operating and Financial Highlights
einnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from einnews.com Daily Mail and Mail on Sunday newspapers.

Johns Hopkins University , United States , University Of Maryland , Salt Lake City , Heum Jeong , James Koprich , Andrew Mielach , Michela Deleidi , Bruce Mackle , Rob Etherington , Clene Nanomedicine , Trademark Office , Tottenham Acquisition , Lifesci Communications , Clene Inc , University Of Texas Southwestern Medical Center , Pohang University Of Science Technology , Lifesci Advisors , Clene Nanomedicine Inc , International Symposium , German Center , Exchange Commission , Atuka Inc , Michaelj Fox Foundation , Motor Unit Number Index , Multiple Sclerosis Functional Composite ,

Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Clene Nanomedicine to Present Updated Interim Data from Phase 2 Multiple Sclerosis Programs at .
Clene Inc.February 19, 2021 GMT
SALT LAKE CITY, Feb. 19, 2021 (GLOBE NEWSWIRE) Clene Inc. (NASDAQ: CLNN) (along with its subsidiaries, “Clene”) and its wholly owned subsidiary Clene Nanomedicine, Inc., a clinical-stage biopharmaceutical company, today announced that it will present updated interim data from its REPAIR-MS study and updated blinded interim data from its VISIONARY-MS study in poster presentations at the Americas Committee for Treatment and Research in Multiple Sclerosis’ ACTRIMS Forum 2021 (“ACTRIMS”) taking place virtually from February 25-27, 2021. ....

Salt Lake City , United States , Andrew Mielach , Robert Glanzman , Bruce Mackle , Lifesci Advisors , Research In Multiple Sclerosi , Americas Committee For Treatment , Clene Nanomedicine Inc , Exchange Commission , Lifesci Communications , Clene Inc , University Of Texas Southwestern Medical Center , Clene Nanomedicine , Americas Committee , Multiple Sclerosi , Patients Treated , Interim Results , Magnetic Resonance Imaging Study , Chief Medical Officer , Catalytic Gold Nanocrystals , Chronic Optic Neuropathy , Multiple Sclerosis Functional Composite , Texas Southwestern Medical Center , North East , Private Securities Litigation Reform Act ,

Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update

Clene Nanomedicine Closes Merger with Tottenham Acquisition I Limited and Provides Corporate Update
Common stock of the merged company, Clene Inc., to commence trading on the NASDAQ Capital Market under the ticker symbol “CLNN” on December 31, 2020
Clinical pipeline includes an ongoing Phase 3 study in amyotrophic lateral sclerosis (ALS) and four concurrent Phase 2 studies in ALS, multiple sclerosis and Parkinson’s disease
Proceeds from the transaction totaled approximately $31.9 million, combining funds held in Tottenham’s trust account and a concurrent $22.4 million PIPE financing
SALT LAKE CITY, Dec. 30, 2020 (GLOBE NEWSWIRE) Clene Nanomedicine, Inc. (“Clene”) (NASDAQ: CLNN), a clinical-stage biopharmaceutical company, today announced the closing of a merger with Tottenham Acquisition I Limited (“Tottenham”) and provided a corporate update. Proceeds from this transaction totaled approximately $31.9 million, which included funds held in Tottenh ....

Salt Lake City , United States , Johns Hopkins University , Kyongsang Bukto , South Korea , University Of Maryland , Heum Jeong , Andrew Mielach , Matt Gardner , Bruce Mackle , Rob Etherington , Exchange Commission On , Hyundai Venture Investment Corporation , Kirkland Ellis , Lifesci Communications , Clene Inc , University Of Texas Southwestern Medical Center , Pohang University Of Science Technology , Board Of Directors Neurobo Pharmaceuticals Inc , Rexahn Pharmaceuticals Inc , Lifesci Advisors , International Symposium , Clene Nanomedicine Inc , Chardan Capital Markets , Lifesci Capital , Exchange Commission ,